Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects

British Journal of Clinical Pharmacology
Ji-Young ParkKi Young Lee

Abstract

Fungal infection is a significant comorbidity in patients with diabetes mellitus, and ketoconazole, an antifungal agent, causes a number of drug interactions with coadministered drugs. Rosiglitazone is a novel thiazolidinedione antidiabetic drug, mainly metabolized by CYP2C8 and to a lesser extent CYP2C9. We investigated the possible effect of ketoconazole on the pharmacokinetics of rosiglitazone in humans. Ten healthy Korean male volunteers were treated twice daily for 5 days with 200 mg ketoconazole or with placebo, using a randomized, open-label, two-way crossover study. On day 5, a single dose of 8 mg rosiglitazone was administered orally, and plasma rosiglitazone concentrations were measured. Ketoconazole increased the mean area under the plasma concentration-time curve for rosiglitazone by 47%[P = 0.0003; 95% confidence interval (CI) 23, 70] and the mean elimination half-life from 3.55 to 5.50 h (P = 0.0003; 95% CI in difference 1.1, 2.4). The peak plasma concentration of rosiglitazone was increased by ketoconazole treatment by 17% (P = 0.03; 95% CI 5, 29). The apparent oral clearance of rosiglitazone decreased by 28% after ketoconazole treatment (P = 0.0005; 95% CI 18, 38). This study revealed that ketoconazole affected ...Continue Reading

References

Jan 1, 1988·Clinical Pharmacokinetics·T K Daneshmend, D W Warnock
Feb 1, 1994·British Journal of Clinical Pharmacology·Y S KrishnaiahD Visweswaram
Jun 1, 1996·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·G C BoltonA D Shore
Mar 26, 1998·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·E AlbengresJ P Tillement
Oct 8, 1998·The Annals of Pharmacotherapy·B M Lomaestro, M A Piatek
Jul 10, 1999·Drugs·J A Balfour, G L Plosker
Sep 14, 1999·Biochemical Pharmacology·L Nadin, M Murray
Oct 6, 1999·British Journal of Clinical Pharmacology·S J BaldwinR J Chenery
Mar 10, 2000·Clinical Pharmacokinetics·K VenkatakrishnanD J Greenblatt
Dec 8, 2000·Clinical Therapeutics·J M Malinowski, S Bolesta
Jan 3, 2001·British Journal of Clinical Pharmacology·C E OngJ O Miners
Feb 24, 2001·The Annals of Pharmacotherapy·M L Thomas, S J Lloyd
Apr 12, 2001·British Journal of Clinical Pharmacology·Y R YoonJ G Shin
Jun 22, 2001·European Journal of Clinical Pharmacology·A K MillerM I Freed
Jan 24, 2002·The Journal of Pharmacology and Experimental Therapeutics·Xue-Qing LiCollen M Masimirembwa
Apr 23, 2002·Pharmacogenomics·Carsten OttoBurkhard Göke
Jun 5, 2002·Journal of Clinical Pharmacology·Mamidi N V S RaoRamanujam Rajagopalan
Jul 20, 2002·Pharmacotherapy·Nancee V Niemeyer, Laurel M Janney
Jan 25, 2003·Clinical Pharmacology and Therapeutics·George K DresserRichard B Kim
Jul 19, 2003·Journal of Chemotherapy·S S BunJ Catalin
Sep 10, 2003·Mayo Clinic Proceedings·Asra Kermani, Abhimanyu Garg
Mar 6, 2004·Clinical Pharmacology and Therapeutics·Ji-Young ParkJae-Gook Shin

❮ Previous
Next ❯

Citations

Jul 23, 2014·Clinical Therapeutics·Eun Sil OhMin Soo Park
Sep 25, 2014·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Muhammad Amin, Naeti Suksomboon
Jan 6, 2010·Expert Opinion on Investigational Drugs·Richard Arakaki, Bernice Welles
Nov 17, 2012·Expert Opinion on Drug Metabolism & Toxicology·Andreas HolsteinPeter Kovacs
Jul 17, 2015·British Journal of Clinical Pharmacology·Jan H BeumerRaman Venkataramanan
Jul 20, 2005·Journal of Clinical Pharmacology·Kyoung-Ah KimJi-Young Park
Jul 22, 2006·British Journal of Clinical Pharmacology·Rasmus S PedersenKim Brosen
Sep 20, 2006·British Journal of Clinical Pharmacology·Kyoung-Ah KimJi-Young Park
Jan 15, 2011·British Journal of Pharmacology·N SzentandrássyP P Nánási
May 13, 2011·British Journal of Pharmacology·J C Hancox
Oct 11, 2014·Rapid Communications in Mass Spectrometry : RCM·Jeongmin JooKwang-Hyeon Liu
Apr 6, 2012·Trends in Pharmacological Sciences·Aleksi TornioJanne T Backman
Nov 14, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·M RuscicaN Mitro
Jan 12, 2017·Drugs in R&D·Maryam BazarganBeverly S Muhlhausler
Feb 14, 2006·Rapid Communications in Mass Spectrometry : RCM·Hyojin KimKwang-Hyeon Liu
Apr 18, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Marta RobertGeorg Golor
Nov 30, 2018·Current Drug Metabolism·Panjasaram Naidoo, Manoranjenni Chetty
Nov 2, 2021·Expert Opinion on Drug Metabolism & Toxicology·Veronica Di PaoloLuigi Quintieri
Nov 28, 2017·Drug Metabolism and Pharmacokinetics·Kenta HarayaYuichi Sugiyama

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.